Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swedish (OMX) Healthcare Sector Analysis

UpdatedFeb 14, 2026
DataAggregated Company Financials
Companies152
  • 7D-2.9%
  • 3M-8.0%
  • 1Y-10.7%
  • YTD-2.9%

Over the last 7 days, the Healthcare industry has dropped 2.9%, driven by Camurus declining 19%. However, the industry is down 11% over the past year. As for the next few years, earnings are expected to grow by 26% per annum.

Sector Valuation and Performance

Has the Swedish Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sat, 14 Feb 2026SEK 565.4bSEK 230.9b-SEK 1,751,199,327.3530.8x-322.8x2.4x
Mon, 12 Jan 2026SEK 599.8bSEK 230.2bSEK 3.7b41x163.5x2.6x
Wed, 10 Dec 2025SEK 582.0bSEK 230.6bSEK 3.5b41.2x164.2x2.5x
Fri, 07 Nov 2025SEK 588.5bSEK 229.2bSEK 2.8b45.4x212.8x2.6x
Sun, 05 Oct 2025SEK 614.1bSEK 227.1bSEK 6.6b43.2x93x2.7x
Tue, 02 Sep 2025SEK 623.8bSEK 227.1bSEK 6.6b46.1x94.7x2.7x
Thu, 31 Jul 2025SEK 632.0bSEK 226.9bSEK 6.5b54.1x96.6x2.8x
Sat, 28 Jun 2025SEK 616.8bSEK 226.8bSEK 5.9b44.9x105.1x2.7x
Mon, 26 May 2025SEK 587.3bSEK 226.0bSEK 6.6b37x89.3x2.6x
Wed, 23 Apr 2025SEK 549.9bSEK 222.1bSEK 5.0b37.5x110.7x2.5x
Fri, 21 Mar 2025SEK 558.9bSEK 206.3bSEK 5.0b37x112x2.7x
Sun, 16 Feb 2025SEK 594.9bSEK 206.4bSEK 2.5b41.7x236.5x2.9x
Tue, 14 Jan 2025SEK 571.2bSEK 201.6b-SEK 2,648,325,362.5039.2x-215.7x2.8x
Thu, 12 Dec 2024SEK 575.6bSEK 202.8b-SEK 2,465,020,947.5338.6x-233.5x2.8x
Sat, 09 Nov 2024SEK 528.5bSEK 200.2b-SEK 2,597,706,631.9538.6x-203.4x2.6x
Mon, 07 Oct 2024SEK 607.5bSEK 200.2b-SEK 2,782,910,611.7639.8x-218.3x3x
Wed, 04 Sep 2024SEK 607.0bSEK 200.0b-SEK 2,809,391,402.8740x-216.1x3x
Fri, 02 Aug 2024SEK 584.7bSEK 199.7b-SEK 2,762,785,972.7841.1x-211.6x2.9x
Sun, 30 Jun 2024SEK 562.0bSEK 195.7b-SEK 3,202,643,667.9236.8x-175.5x2.9x
Tue, 28 May 2024SEK 552.0bSEK 196.0b-SEK 2,798,220,083.8936.2x-197.3x2.8x
Thu, 25 Apr 2024SEK 521.0bSEK 194.1b-SEK 3,331,281,004.7543.9x-156.4x2.7x
Sat, 23 Mar 2024SEK 519.8bSEK 192.7b-SEK 3,669,066,937.9843.3x-141.7x2.7x
Mon, 19 Feb 2024SEK 516.9bSEK 191.7b-SEK 4,080,444,504.7249.9x-126.7x2.7x
Wed, 17 Jan 2024SEK 551.4bSEK 191.7b-SEK 967,683,823.0048.2x-569.8x2.9x
Fri, 15 Dec 2023SEK 517.8bSEK 191.2b-SEK 999,563,618.0048.9x-518x2.7x
Sun, 12 Nov 2023SEK 470.7bSEK 190.4b-SEK 1,080,492,686.0049.4x-435.7x2.5x
Tue, 10 Oct 2023SEK 439.1bSEK 185.1b-SEK 2,032,014,505.0033.8x-216.1x2.4x
Thu, 07 Sep 2023SEK 457.1bSEK 185.8b-SEK 2,013,608,879.0035.8x-227x2.5x
Sat, 05 Aug 2023SEK 473.1bSEK 183.9b-SEK 1,003,843,769.0039.9x-471.3x2.6x
Mon, 03 Jul 2023SEK 480.3bSEK 179.2b-SEK 793,306,793.0044.7x-605.5x2.7x
Wed, 31 May 2023SEK 504.9bSEK 178.9b-SEK 549,905,700.0043.5x-918.2x2.8x
Fri, 28 Apr 2023SEK 513.3bSEK 174.8b-SEK 1,487,139,903.0035.1x-345.1x2.9x
Sun, 26 Mar 2023SEK 482.3bSEK 172.4b-SEK 1,417,086,752.0035.3x-340.4x2.8x
Tue, 21 Feb 2023SEK 505.5bSEK 169.8b-SEK 615,986,485.0038.8x-820.7x3x
Price to Earnings Ratio

-820.7x


Total Market Cap: SEK 505.5bTotal Earnings: -SEK 615,986,485.00Total Revenue: SEK 169.8bTotal Market Cap vs Earnings and Revenue0%0%0%
Swedish Healthcare Sector Price to Earnings3Y Average -171.2x202420252026
Current Industry PE
  • Investors are pessimistic on the Swedish Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The 3-year average PS ratio of 2.7x is higher than the industry's current PS ratio of 2.4x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have deteriorated over the last three years.
  • Meanwhile revenues for these companies have grown 11% per year.
  • This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has caused losses to expand.

Industry Trends

Which industries have driven the changes within the Swedish Healthcare sector?

SE Market-1.01%
Healthcare-2.91%
Biotech2.57%
Medical Equipment-0.54%
Healthcare Services-6.67%
Life Sciences-9.69%
Healthtech-10.18%
Pharma-14.96%
Industry PE
  • Investors are most optimistic about the Healthtech industry even though it's trading below its 3-year average PE ratio of 117x.
    • Analysts are expecting annual earnings growth of 17.9%, which is lower than the prior year's growth of 46.7% per year.
Forecasted Growth
  • Analysts are most optimistic on the Pharma industry, expecting annual earnings growth of 37% over the next 5 years.
  • This is better than its past earnings growth rate of 14% per year.
  • In contrast, the Life Sciences industry is expected to see its earnings grow by 17% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
SOBI Swedish Orphan BiovitrumSEK 407.603.0%
+SEK 4.1b		31.7%PE294.8x
BIOA B BioArcticSEK 322.205.0%
+SEK 1.4b		51.7%PE28.6x
MCOV B MedicoverSEK 209.002.7%
+SEK 830.4m		1.0%PE38.4x
VIMIAN Vimian GroupSEK 27.844.6%
+SEK 645.7m		-39.4%PE44.4x
BONEX Bonesupport HoldingSEK 180.805.4%
+SEK 612.5m		-45.1%PE78.4x

Latest News

MCAP
SEK 480.00
MedCap
7D
-11.8%
1Y
20.9%
MCOV B
SEK 209.00
Medicover
7D
2.7%
1Y
1.0%
BIOG B
SEK 103.70
BioGaia
7D
-5.0%
1Y
-19.2%
VIMIAN
SEK 27.84
Vimian Group
7D
4.6%
1Y
-39.4%
CAMX
SEK 553.50
Camurus
7D
-19.4%
1Y
-6.8%
STIL
SEK 181.00
Stille
7D
20.7%
1Y
-28.2%
ASKER
SEK 65.08
Asker Healthcare Group
7D
-15.8%
1Y
n/a
AMBEA
SEK 115.90
Ambea
7D
-17.2%
1Y
7.5%
BONEX
SEK 180.80
Bonesupport Holding
7D
5.4%
1Y
-45.1%

Is There An Opportunity With Bonesupport Holding AB (publ)'s (STO:BONEX) 43% Undervaluation?

Feb 12
Is There An Opportunity With Bonesupport Holding AB (publ)'s (STO:BONEX) 43% Undervaluation?
ALIF B
SEK 138.10
AddLife
7D
-9.1%
1Y
-21.1%

Investors Shouldn't Be Too Comfortable With AddLife's (STO:ALIF B) Earnings

Feb 12
Investors Shouldn't Be Too Comfortable With AddLife's (STO:ALIF B) Earnings
GETI B
SEK 201.20
Getinge
7D
-1.3%
1Y
-5.2%

GETI B: Higher P/E Expectations Will Outrun Softer Margins And Dividend Uplift

Analysts have adjusted their price target on Getinge from SEK165.00 to about SEK171.00, reflecting updated assumptions on fair value, discount rate, revenue growth, profit margin and future P/E expectations. What's in the News Getinge AB (publ) has a proposed dividend of SEK 4.75 per share, compared with SEK 4.60 per share previously, subject to approval (Key Developments).
BIOA B
SEK 322.20
BioArctic
7D
5.0%
1Y
51.7%
SOBI
SEK 407.60
Swedish Orphan Biovitrum
7D
3.0%
1Y
31.7%
MVIR
SEK 1.18
Medivir
7D
110.4%
1Y
-50.3%
SECT B
SEK 181.70
Sectra
7D
-12.9%
1Y
-29.3%

SECT B: Cloud Contracts And Pathology Expansion Will Support Future Upside Potential

Analysts have reaffirmed their price target on Sectra at SEK 245.00, with only marginal tweaks to underlying model inputs such as discount rate, revenue growth, profit margin and future P/E assumptions, supporting an unchanged view of fair value. What's in the News TUM Klinikum in Germany is expanding its Sectra enterprise imaging setup with pathology and ophthalmology modules under a five year contract covering up to 300,000 examinations per year, aimed at higher efficiency and closer collaboration across departments (Client announcement).
HNSA
SEK 40.00
Hansa Biopharma
7D
10.4%
1Y
72.4%

HNSA: US Kidney Transplant Approval Timing Will Drive Downside Risk

Analysts have nudged their price target for Hansa Biopharma to SEK 69, reflecting updated assumptions on growth, profitability and valuation multiples, supported by views that imlifidase underpins a more de-risked commercial profile across kidney transplantation, autoimmune disease and gene therapy. Analyst Commentary Recent Street research frames Hansa Biopharma as a company with a clearly defined lead asset and a focused commercial plan across kidney transplantation, autoimmune disease and gene therapy.